Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMBRANDT trial of obicetrapib + ezetimibe fixed-dose combination in ASCVD
2023-508475-36-00Phase 3Authorised
- Sponsor
- NewAmsterdam Pharma
- Start
- Oct 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease comparing Obicetrapib + ezetimibe FDC with Placebo (2 arms). Primary endpoint: Percent change in total non-calcified plaque volume. Planned start Oct 2024; status: authorised.
02
Drugs
obicetrapibezetimibe
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on 2023-508475-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508475-36-00.